Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine
Journal of Clinical Investigation · 03.09.2024 · 134 (17)
DOI: 10.1172/jci181244 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 11.07.2024. Verfasst von Wen Shi Lee und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australi…. Hauptthemen laut MEDLINE: COVID-19, Immunization, Secondary, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian National Health and Medical Research Council.
Abstract (Originalsprache)
BACKGROUND There is uncertainty about the timing of booster vaccination against COVID-19 in highly vaccinated populations during the present endemic phase of COVID-19. Studies focused on primary vaccination have previously suggested improved immunity with a longer interval between the first and second vaccine doses. METHODS We conducted a randomized, controlled trial (November 2022–August 2023) and assigned 52 fully vaccinated adults to an immediate or a 3-month delayed bivalent Spikevax mRNA booster vaccine. Follow-up visits were completed for 48 participants ( n = 24 per arm), with collection of saliva and plasma samples following each visit. RESULTS The rise in neutralizing antibody responses to ancestral and Omicron strains were almost identical between the immediate and delayed vaccination arms. Analyses of plasma and salivary antibody responses (IgG, IgA), plasma antibody-dependent phagocytic activity, and the decay kinetics of antibody responses were similar between the 2 arms. Symptomatic and asymptomatic SARS-CoV-2 infections occurred in 49% (21 of 49) participants over the median 11.5 months of follow-up and were also similar between the 2 arms. CONCLUSIONS Our data suggest that there was no benefit in delaying COVID-19 mRNA booster vaccination in preimmune populations during the present endemic phase of COVID-19. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry number 12622000411741 (https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000411741). FUNDING National Health and Medical Research Council, Australia (program grant App1149990) and Medical Research Future Fund (App2005544).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
- Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia.
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Förderung
- Australian National Health and Medical Research Council
Zitieren
APA
Lee, W. S., Audsley, J., Trieu, M. C., Reynaldi, A., Aurelia, L. C., Mehta, P. H., Patterson, J., Kent, H. E., Nguyen, J., Amarasena, T., Esterbauer, R., Haycroft, E. R., Ramanathan, P., Davenport, M. P., Schlub, T. E., Sasadeusz, J., Wheatley, A. K., Chung, A. W., Juno, J. A., …, & Kent, S. J. (2024). Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine. Journal of Clinical Investigation, 134(17). https://doi.org/10.1172/jci181244
Vancouver
Lee WS, Audsley J, Trieu MC, Reynaldi A, Aurelia LC, Mehta PH, et al. Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine. Journal of Clinical Investigation. 2024;134(17). doi:10.1172/jci181244
BibTeX
@article{Lee2024,
author = {Lee, Wen Shi and Audsley, Jennifer and Trieu, Mai-Chi and Reynaldi, Arnold and Aurelia, L Carissa and Mehta, Palak H and Patterson, Joanne and Kent, Helen E and Nguyen, Julie and Amarasena, Thakshila and Esterbauer, Robyn and Haycroft, Ebene R and Ramanathan, Pradhipa and Davenport, Miles P and Schlub, Timothy E and Sasadeusz, Joseph and Wheatley, Adam K and Chung, Amy W and Juno, Jennifer A and Selva, Kevin J and Kent, Stephen J},
title = {Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {17},
doi = {10.1172/jci181244}
}
EUVIMED